HUMAN ADULT HSCS CAN BE DISCRIMINATED FROM LINEAGE-COMMITTED HPCS BY THE EXPRESSION OF ENDOMUCIN

EHA Library, Kristian Reckzeh, 214880

ROS-DEPENDENT SELF-RENEWAL DEFECTS OF HUMAN HEMATOPOIETIC STEM CELLS AFTER EXPOSURE TO LOW DOSE OF IONIZING RADIATIONS

EHA Library, Marie-Laure Arcangeli, 214881

THE HISTONE CHAPERONE NAP1L3 IS REQUIRED FOR HEMATOPOIETIC STEM CELL MAINTENANCE AND DIFFERENTIATION

EHA Library, GÖZDE TURKÖZ, 214882

PROSPECTIVELY ISOLATED BONE MARROW STROMAL CELLS FROM PATIENTS WITH HEMATOLOGICAL MALIGNANCIES DIFFER PHENOTYPICALLY AND RELATE TO DISEASE STAGE IN MGUS/MYELOMA

EHA Library, Stefan SCHEDING, 214883

PROGRAMMED DEATH LIGAND 1 EXPRESSION IN THE MICROENVIRONMENT OF CLASSICAL HODGKIN LYMPHOMA IS INDUCED BY LYMPHOMA CELLS VIA AN IL27-DEPENDENT MECHANISM

EHA Library, Joseph Taylor, 214884

TARGETING ROR1 RECEPTOR IN CLASSICAL HODGKIN LYMPHOMA: EFFECTS ON APOPTOSIS AND PROLIFERATION AND ITS EMERGING THERAPEUTIC IMPLICATIONS

EHA Library, Louloudenia Velentza, 214885

TREATMENT RELATED INCIDENCE OF DISEASES OF THE CIRCULATORY SYSTEM IN PATIENTS DIAGNOSED WITH HODGKIN LYMPHOMA

EHA Library, Caroline Weibull, 214886

ACTIVATED CASPASE-3 EXPRESSION BY HODGKIN AND REED-STERNBERG CELLS (HRS) IS A POWERFUL PROGNOSTIC FACTOR IN CLASSICAL HODGKIN LYMPHOMA (CHL) TREATED WITH ABVD OR EQUIVALENT REGIMENS

EHA Library, Theodoros Vassilakopoulos, 214887

RISK OF SECOND MALIGNANCIES IN HODGKIN LYMPHOMA PATIENTS IN THE NEW MILLENNIUM: REAL WORLD EVIDENCE FROM THE SEER DATABASE

EHA Library, Velizar Shivarov, 214888

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION AFTER NIVOLUMAB TREATMENT IN RELAPSED/REFRACTORY HODGKIN LYMPHOMA

EHA Library, Jean-Baptiste Mear, 214889

INTERIM- PET RESULTS FOR PROGNOSIS IN ADULTS WITH HODGKIN LYMPHOMA: A PROGNOSTIC FACTOR EXEMPLAR REVIEW (PRELIMINARY RESULTS)

EHA Library, Angela Aldin, 214890

DOWNREGULATION OF STATS DETERMINE POOR PROGNOSIS IN HODGKIN’S LYMPHOMA.

EHA Library, Ahmad Zargari, 214891

A PHASE 1 STUDY INVESTIGATING THE COMBINATION OF AFM13 AND PEMBROLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY HODGKIN LYMPHOMA AFTER BRENTUXIMAB VEDOTIN FAILURE: UPDATED SAFETY AND EFFICACY DATA.

EHA Library, Andras Strassz, 214892

PAEDIATRIC HODGKIN LYMPHOMA IN VERY YOUNG PATIENTS: THE ITALIAN EXPERIENCE

EHA Library, Piero Farruggia, 214893

NIVOLUMAB IN COMBINATION WITH BRENTUXIMAB VEDOTIN IN PATIENTS WITH RELAPSED OR REFRACTORY HODGKIN’S LYMPHOMA AFTER FAILURE OF NIVOLUMAB MONOTHERAPY

EHA Library, Luibov Tsvetkova, 214894

THE COMBINATION OF ALISERTIB AND ROMIDEPSIN IS A SAFE AND EFFECTIVE REGIMEN FOR RELAPSED/REFRACTORY AGGRESSIVE HODGKIN AND T-CELL LYMPHOMAS: A PHASE 1 STUDY

EHA Library, Paolo Strati, 214895

ΔSUVMAX AND ΔSUVPEAK IMPROVE THE NEGATIVE PREDICTIVE VALUE OF INTERIM PET SCAN IN HODGKIN LYMPHOMA

EHA Library, Teresa Ribeiro, 214896

OUTCOME OF ELDERLY PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA IN CENTRAL SCOTLAND, UK

EHA Library, Mark Rafferty, 214897

LONG-TERM FOLLOW-UP OF VEMURAFENIB IN BRAF MUTANT HAIRY CELL LEUKEMIA SHOWS DURABLE REMISSIONS AND HIGH RESPONSE RATES WITH REPEATED TREATMENT WITH VEMURAFENIB AT RELAPSE

EHA Library, Jae H. Park, 214898

METABOLIC (PET) AND MRD RESPONSE CONFER REDUCED RISK OF PROGRESSION OR DEATH IN PATIENTS TREATED WITHIN THE PHASE III GALLIUM STUDY

EHA Library, Christiane Pott, 214899

THE DUAL SYK/JAK INHIBITOR CERDULATINIB DEMONSTRATES RAPID TUMOR RESPONSES IN A PHASE 2A STUDY IN PATIENTS WITH RELAPSED/REFRACTORY B- AND T-CELL NON-HODGKIN LYMPHOMA (NHL)

EHA Library, Paul A. Hamlin, 214900

ACALABRUTINIB ALONE OR IN COMBINATION WITH RITUXIMAB IN FOLLICULAR LYMPHOMA

EHA Library, Nathan H. Fowler, 214901

RESPONSE RATE TO LENALIDOMIDE PLUS RITUXIMAB (R2) IS INDEPENDENT OF RITUXIMAB-REFRACTORY STATUS: INITIAL INTERIM ANALYSIS OF MAGNIFY PHASE IIIB STUDY OF R2 FOLLOWED BY MAINTENANCE IN R/R INDOLENT NHL

EHA Library, Mathias J. Rummel, 214902

RESULTS OF A DOSE ESCALATION STUDY OF ME-401, A SELECTIVE PI3KΔ INHIBITOR, IN RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL) AND CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL)

EHA Library, John M Pagel, 214903

SHORT DIAGNOSIS TO TREATMENT INTERVAL IS ASSOCIATED WITH POOR OUTCOMES IN PATIENTS WITH FOLLICULAR LYMPHOMA TREATED WITH IMMUNOCHEMOTHERAPY

EHA Library, Michael Clausen, 214904

NEW ASSESSMENT INDEX OF CLINICAL TRANSFORMATION FROM FOLLICULAR LYMPHOMA (FL) TO DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) IN THE RITUXIMAB ERA

EHA Library, Takafumi Shichijo, 214905

LONG TERM INTEGRATED SAFETY ANALYSIS OF UMBRALISIB (TGR-1202), A PI3K-DELTA/CK1-EPSILON INHIBITOR WITH A DIFFERENTIATED SAFETY PROFILE, IN PATIENTS WITH RELAPSED/REFRACTORY LYMPHOID MALIGNANCIES

EHA Library, Matthew S. Davids, MD, MMSC, 214906

POOLED ANALYSIS OF SAFETY DATA FROM ZANUBRUTINIB (BGB-3111) MONOTHERAPY STUDIES IN HEMATOLOGIC MALIGNANCIES

EHA Library, Constantine S Tam, 214907

R-ESHAP IS NOT EFFECTIVE AS SALVAGE THERAPY IN REFRACTORY FOLLICULAR LYMPHOMA: RESULTS OF A RETROSPECTIVE MULTICENTRE STUDY ON BEHALF OF GELCAB GROUP

EHA Library, Ana Muntañola, 214908

CHALLENGES IN DELIVERY OF MAINTENANCE ANTI-CD20 THERAPY IN ADVANCED FOLLICULAR LYMPHOMA: 5-YEAR EXPERIENCE AT THE ROYAL MARSDEN HOSPITAL

EHA Library, Hamzeh Kayhanian, 214909

OUTCOMES FOR DIABETIC PATIENTS FROM THE CHRONOS-1 STUDY WITH RELAPSED OR REFRACTORY INDOLENT B-CELL LYMPHOMA TREATED WITH COPANLISIB

EHA Library, Martin Dreyling, 214910

COMPARATIVE EFFICACY AND SAFETY OF DIFFERENT ANTIVIRAL AGENTS FOR CYTOMEGALOVIRUS PROPHYLAXIS AFTER HEMATOPOIETIC-CELL TRANSPLANTATION: A SYSTEMATIC REVIEW AND META-ANALYSES

EHA Library, Nico Gagelmann, 214911

CANDIDA-REACTIVE T CELLS FOR THE DIAGNOSIS OF INVASIVE CANDIDA INFECTION

EHA Library, Felix Koehler, 214912

TENOFOVIR VERSUS LAMIVUDINE FOR PREVENTION OF HEPATITIS B VIRUS REACTIVATION AMONG PATIENTS WITH AGGRESSIVE LYMPHOMAS UNDERGOING FRONT-LINE ANTHRACYCLINE-CONTAINING CHEMOTHERAPY

EHA Library, Irene Zacheo, 214913

SWITCHING FROM POSACONAZOLE ORAL SUSPENSION TO TABLETS INCREASES SERUM LEVELS, PRESERVES SAFETY AND IMPROVES TREATMENT SATISFACTION: A PROSPECTIVE CLINICAL TRIAL IN PATIENTS WITH ACUTE LEUKEMIA.

EHA Library, Rafael F Duarte, 214914

MURCORMYCOSIS AND ASPERGILLOSIS IN ONCOHEMATOLOGICAL PATIENTS: WHAT’S THE DIFFERENCE?

EHA Library, Nikolay Klimko, 214915

INVASIVE FUNGAL DISEASES CAUSED BY RARE PATHOGENS IN CHILDREN WITH HEMATOLOGICAL DISEASES AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION AND CHEMOTHERAPY

EHA Library, Marina Popova, 214916

INVASIVE ASPERGILLOSIS IN HAEMATOLOGICAL PATIENTS: A REVIEW OF 625 CASES

EHA Library, Raoul Herbrecht, 214917

DIAGNOSIS OF INVASIVE ASPERGILLOSIS IN HIGH RISK HEMATOLOGICAL MALIGNANCY PATIENTS: PERFORMANCE OF BIOMARKERS AND CYTOKINES IN SAME DAY BLOOD AND BRONCHOALVEOLAR LAVAGE FLUID SAMPLES.

EHA Library, Martin Hoenigl, 214918

NEUTROPHIL EXTRACELLULAR TRAPS IMPAIR FUNGAL CLEARANCE IN A MOUSE MODEL OF INVASIVE PULMONARY ASPERGILLOSIS

EHA Library, Astrid Alflen, 214919

HEMOPHAGOCYTIC LIMPHOHISTIOCYTOSIS ASSOCIATED WITH LEISHMANIASIS: A HIDDEN PASSENGER IN ENDEMIC AREAS?

EHA Library, Jon Badiola, 214920

ANALYSIS OF THE BURDEN OF CYTOMEGALOVIRUS REACTIVATION IN PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION

EHA Library, Christopher Tham, 214921

ANTIGFUNGAL DRUGS MODULATE HUMAN NEUTROPHIL ACTIVITIES IN VITRO AND IN VIVO IN PATIENTS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

EHA Library, Daniel Teschner, 214922

(1-3)-Β-D-GLUCAN ASSAY AND AIRWAY-INVASIVE RADIOLOGICAL FINDINGS AS EARLY SIGNS OF PULMONARY ASPERGILLOSIS IN HIGH-RISK HEMATOLOGIC PATIENTS IN THE POSACONAZOLE ERA: PRELIMINARY OBSERVATIONS

EHA Library, Claudia Giordano, 214923

COMPARATIVE ANALYSIS OF DETECTION OF EBV SMALL NON-CODING RNA (EBER) AND MARKERS OF ACUTE EBV INFECTION AT THE ONSET OF ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA

EHA Library, Natalia Chernova, 214924

THE ROLE OF SERUM GALACTOMANNAN ASSAY IN THE MANAGEMENT OF INVASIVE MOLD INFECTIONS IN AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION.

EHA Library, María Esther Martínez-Muñoz, 214925

CYTOMEGALOVIRUS (CMV) IMPACT ON CLINICAL OUTCOMES AND RESOURCE USE AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: THE INFLUENCE OF RECURRENT EPISODES OF CMV INFECTION

EHA Library, Carlos de Miguel Jiménez, 214926

EPIDEMIOLOGY AND TREATMENT APPROACHES OF INVASIVE FUNGAL INFECTIONS MANAGEMENT IN HEMATOLOGICAL MALIGNANCIES: RESULTS FROM A SINGLE-CENTRE STUDY

EHA Library, Nicola Stefano Fracchiolla, 214927

HERPES VIRUSES AT THE ONSET OF ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA. IS THERE AN ASSOCIATION?

EHA Library, Natalia Chernova, 214928

POST-TRANSPLANT EBSTEIN-BARR VIRAL LOAD MONITORING EXPERIENCE IN A HEMATOPOIETIC STEM CELL TRANSPLANTATION CENTER

EHA Library, Seda Balaban, 214929

ISAVUCONAZOLE SHORTENS THE QTC INTERVAL

EHA Library, Sibylle Mellinghoff, 214930

ALPHA LIPOIC ACID REDUCES THE TOXIC EFFECTS INDUCED BY IRON OVERLOAD TREATMENT: IN VITRO AND IN VIVO MODELS

EHA Library, Giuseppina CAMIOLO, 214931

A PHASE 1, PLACEBO-CONTROLLED STUDY TO DETERMINE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF ESCALATING SUBCUTANEOUS DOSES OF LJPC-401 (SYNTHETIC HUMAN HEPCIDIN) IN HEALTHY ADULTS

EHA Library, Antonis Kattamis, 214932

REPEATABILITY OF LIVER IRON CONCENTRATION MEASUREMENTS WITH MRI AND AN ARTIFICIAL NEURAL NETWORK DATA ANALYSIS SYSTEM

EHA Library, Tim St Pierre, 214933

IRON OVERLOAD FOLLOWING ALLOGENEIC HEMATOPOIETIC TRANSPLANTS: LONG-TERM OUTCOMES

EHA Library, Gloria Obi, 214934

IRON OVERLOAD INCREASES OXIDATIVE STRESS AND DECREASES CLONOGENIC CAPACITY OF CELLS IN MDS PATIENTS: CAN BE RESTORED AFTER DEFERASIROX TREATMENT?

EHA Library, María Díez Campelo, 214935

RISK OF OVERTREATMENT OF HAEMOCHROMATOSIS DUE TO CO-INHERITED HYPERFERRITINAEMIA-CATARACT SYNDROME

EHA Library, Hannah Cutts, 214936

AN OPEN-LABEL, MULTICENTER, SINGLE-ARM, PHASE II STUDY ASSESSING PATIENT PREFERENCE FOR THE DEFERASIROX FILM-COATED TABLET COMPARED TO THE REFERENCE DISPERSIBLE TABLET FORMULATION: THE JUPITER STUDY

EHA Library, Vip Viprakasit, 214937

A RARE CAUSE OF HEREDITARY HEMOCHROMATOSIS : COMPOUND HETEROZYGOSITY ASSOCIATING THE C282Y VARIATION WITH A PRIVATE HFE MUTATION - TWO CASES COMBINING NEW NONSENSE MUTATIONS.

EHA Library, severine cunat, 214938

THE RETICULOCYTE PARAMETERS: A NEW TOOL FOR ASSESSING AND MONITORING IRON HOMEOSTASIS

EHA Library, Maria Jose Teles, 214939

SYNERGISTIC EFFECTS OF PRIMA-1MET (APR-246) AND AZACITIDINE (AZA) IN TP53-MUTATED MYELODYSPLASTIC SYNDROMES

EHA Library, Stephane Giraudier, 214940

GENE PANEL ANALYSIS BY NEXT GENERATION SEQUENCING FOR THE DETECTION OF CLONAL HAEMATOPOIESIS IN IDIOPATHIC CYTOPENIA OF UNDETERMINED SIGNIFICANCE (ICUS) AND MYELODYSPLASTIC SYNDROME (MDS)

EHA Library, Yannick Wouters, 214941

IMPACT OF SOMATIC MUTATIONAL TESTING BY NEXT-GENERATION SEQUENCING (NGS) FOR SUSPECTED MYELODYSPLASIA OR MYELODYSPLASTIC/MYELOPROLIFERATIVE SYNDROMES IN “REAL-LIFE”.

EHA Library, Yannick Le Bris, 214942

PROGENITOR HYPERSENSITIVITY TO FLT3L GENERATES CLONAL PLASMACYTOID DENDRITIC CELLS IN CHRONIC MYELOMONOCYTIC LEUKEMIA

EHA Library, Nolwenn Lucas, 214943

ASXL1 IS A MOLECULAR PREDICTOR IN IDIOPATHIC CYTOPENIA OF UNDETERMINED SIGNIFICANCE

EHA Library, Dong-Yeop Shin, 214944

MUTATIONAL PROFILE IN LOW RISK MDS WITHOUT RING SIDEROBLASTS

EHA Library, Maria Abaigar, 214945

COMPARISON OF MUTATION DYNAMICS IN HIGHER RISK MYELODYSPLASTIC SYNDROME PATIENTS TREATED WITH AZACITIDINE AND DECITABINE

EHA Library, Joon Ho Moon, 214946

USING PU.1 AND JUN DIMERIZATION PROTEIN 2 TRANSCRIPTION FACTOR EXPRESSION IN MYELODYSPLASTIC SYNDROMES TO PREDICT TREATMENT RESPONSE AND LEUKEMIA TRANSFORMATION

EHA Library, Ciro Rinaldi, 214947

ASSOCIATION OF EMERGENT PTPN11 MUTATIONS WITH CLINICAL RESISTANCE TO THE COMBINATION OF AZACTIDINE AND RIGOSERTIB IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROME

EHA Library, Lewis Silverman, 214948

A NOVEL CULTURE MODEL FOR STUDYING TERMINAL ERYTHROID DIFFERENTIATION IN PATIENTS WITH SF3B1 MUTATED MYELODYSPLASTIC SYNDROMES

EHA Library, Edda Elvarsdóttir, 214949

PROGNOSTIC SIGNIFICANCE OF THE ASXL1 GENE ALTERATION IN PATIENTS WITH ISOLATED 20Q DELETION

EHA Library, Jana Brezinova, 214950

PARP1 EXPRESSION PROFILE AND DIVERGENT CLINICAL IMPACT IN MYELODYSPLASTIC SYNDROMES AND CHRONIC MYELOMONOCYTIC LEUKEMIA.

EHA Library, Ana María Hurtado López, 214951

MECHANISTIC CHARACTERIZATION OF HDACI MEDIATED KIT DOWNREGULATION IN SYSTEMIC MASTOCYTOSIS

EHA Library, Katarina Lyberg, 214953

MYELODYSPLASTIC SYNDROMES WITH HYPOCELLULAR MARROW: CLINICAL CHARACTERISTICS AND EVALUATION OF OUTCOME

EHA Library, Valeria Santini, 214954

DESCRIPTION OF MUTATIONAL PROFILE IN PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES AT THE TIME OF LEUKEMIC PROGRESSION

EHA Library, Begoña Pedrote-Amador, 214955

CLONAL EVOLUTION IS MUCH MORE FREQUENT IN MDS AS KNOWN AS YET

EHA Library, Christina Ganster, 214956

MUTATIONAL AND SUBGROUP ANALYSES OF LOWER-RISK MYELODYSPLASTIC SYNDROMES (MDS) PATIENTS TREATED WITH LUSPATERCEPT: PHASE 2 PACE-MDS STUDY

EHA Library, Uwe Platzbecker, 214957

ROLE OF SOMATIC MUTATIONS IN PATIENTS WITH LOW-RISK MYELODYSPLASTIC SYNDROMES TREATED WITH ERYTHROPOIESIS STIMULATING AGENTS

EHA Library, María Díez Campelo, 214958

MOLECULAR SCORING SYSTEM INTEGRATED WITH IPSS-R IN KOREAN MYELODYSPLASTIC SYNDROME

EHA Library, Hee Sue Park, 214959

FLOW CYTOMETRY ANALYSIS OF ERYTHROPOIETIC MATURATION PATTERNS HELP TO DIAGNOSE AND FOLLOW-UP ERYTHROPOIETIC DYSPLASIA IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES

EHA Library, Despoina Violidaki, 214960

MUTATIONS AND KARYOTYPE PREDICT TREATMENT RESPONSE IN MYELODYSPLASTIC SYNDROMES

EHA Library, Dame Idossa, 214961

GENDER AND THE PATTERN OF RECURRENT MYELOID MUTATIONS ARE STRONGLY AND INDEPENDENTLY ASSOCIATED TO BLOOD TRANSFUSION INTENSITY IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES

EHA Library, Jenny Rydén, 214962

DIFFERENCES IN MUTATIONAL PROFILE AND CLONAL ARCHITECTURE OF MYELODYSPLASTIC SYNDROMES WITH ISOLATED DELETION OF 5Q, HYPERPLASTIC AND HYPOPLASTIC MYELODYSPLASTIC SYNDROMES

EHA Library, Francisca Hernandez Mohedo, 214963

CLINICAL SIGNIFICANCE OF REDUCED EXPRESSION OF THE GENES LOCATED WITHIN COMMON DELETED REGION OF DEL(20Q) IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES

EHA Library, Masayuki SHISEKI, 214964

HIGH WT1 EXPRESSION LEVELS AT DIAGNOSIS PREDICTED POOR OUTCOMES OF PATIENTS PRESENTING ISOLATED THROMBOCYTOPENIA AT ONSET OF MYELODYSPLASTIC SYNDROME

EHA Library, Qiu-Sha Huang, 214965

ROLE OF DNA METHYLATION GENE AND TP53 MUTATIONS IN PREDICTING THE CLINICAL EFFICACY OF EPIGENETIC THERAPY IN MYELOID NEOPLASM PATIENTS - META ANALYSIS

EHA Library, Li Cai, 214966

MUTATIONS IN 19S PROTEASOME SUBUNITS REPRESENT A NOVEL MECHANISM OF ACQUIRED RESISTANCE TO PROTEASOME INHIBITORS IN MULTIPLE MYELOMA PATIENTS

EHA Library, Santiago Barrio, 214967

KRAS BUT NOT NRAS MUTATIONS ARE ASSOCIATED WITH A FAVORABLE OVERALL SURVIVAL IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH INTENSIVE THERAPY

EHA Library, Jan Krönke, 214968

MOLECULAR MECHANISMS OF THE ACTIVITY OF THE NOVEL C-MYC TARGETED-COMPOUND IDP-501 IN MM

EHA Library, Enrique Ocio, 214969

SNPS ARRAY ANALYSIS OF COPY NUMBER ALTERATIONS (CNAS) IN NEWLY DIAGNOSED TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA (MM) PATIENTS: DEFINITION OF A PROGNOSTIC RISK-CLASSIFIER.

EHA Library, Carolina Terragna, 214970

CD26 IS A POTENTIAL THERAPEUTIC TARGET BY HUMANIZED MONOCLONAL ANTIBODY IN MULTIPLE MYELOMA

EHA Library, Hiroko Nishida, 214971

DNA REPAIR PROCESSES TARGET TRANSCRIBED REGION IN MULTIPLE MYELOMA

EHA Library, Nikhil Munshi, 214972

EFFECT OF DARATUMUMAB ON NORMAL PLASMA CELLS, POLYCLONAL IMMUNOGLOBULINS AND VACCINATION RESPONSES IN EXTENSIVELY PRETREATED MYELOMA PATIENTS

EHA Library, Kristine Frerichs, 214973

STUDY OF PLASMA CELL TRASCRIPTOME IN SMOLDERING MYELOMA PATIENTS IN RELATIONSHIP TO PROGRESSION TO ACTIVE MULTIPLE MYELOMA.

EHA Library, Paola Storti, 214974

LONGITUDINAL CHROMOSOMAL ABNORMALITIES ANALYSIS IN MULTIPLE MYELOMA DISEASE PROGRESSION REVEALS CLONAL EVOLUTION AFTER THERAPY.

EHA Library, Stefania Oliva, 214975

MYTYPE TARGETED NEXT GENERATION SEQUENCING ASSAY FOR DETECTION OF IGH TRANSLOCATIONS AND COPY NUMBER ALTERATIONS IN MULTIPLE MYELOMA

EHA Library, Malin Hultcrantz, 214976

RAPID AND SCALABLE GENOME-WIDE PROFILING OF CLINICALLY RELEVANT GENETIC ABERRATIONS IN MULTIPLE MYELOMA

EHA Library, Donat Alpar, 214977

INDUCTION OF STRUCTURAL AND FUNCTIONAL EFFECTS ON MYELOMA CELLS AFTER DARATUMUMAB TREATMENT

EHA Library, Angelo Corso Faini, 214978

RNA-SEQ BASED RISK STRATIFICATION IN MULTIPLE MYELOMA PATIENTS VALIDATES SKY92 AS A HIGH RISK MARKER IN THE COMMPASS TRIAL

EHA Library, Rowan Kuiper, 214979

MDSCS CONTRIBUTE TO CANCER STEM CELLS ACCUMULATION VIA PIRNA 823 UPREGULATION AND DE NOVO DNA METHYLATION IN MULTIPLE MYELOMA

EHA Library, Lisha Ai, 214980